Biotech Values

[zipjet]

ITMN - I listened to the call and it seemed like ITMN would be able to avoid any type of price reduction?

If I may chime in.

Structurally under the statutory framework, it appears that there can be no price cut effective before 9/15/12 unless the company agrees to it.

They could agree to a reduction before that but are unlikely to do so unless it is a small cut that is justified by the added certainty and utility of the decision moving other jurisdictions forward. But even certainty and utility are questionable benefits since it is not clear that the pricing may not made public.

IMO, Jefferies has this wrong. Delaying progression of IPF will offer significant benefits to the patient in length and QoL.

ij

PS QVT buying:

http://www.sec.gov/Archives/edgar/data/1087432/000119312512109757/d313787dsc13ga.htm